Kyntra Bio, Inc. (KYNB)
Kyntra Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $7.02, down 0.71% on the session, giving a market capitalisation of $28.4M. On trailing twelve-month figures it carries a trailing P/E of 0.13, a net margin of 2199.4%. Its beta of 1.04 implies it has historically moved more than the broad market.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Kyntra Bio, Inc. is most often compared with the following Healthcare names: